Department of Cardiology, Renmin Hospital of Wuhan University.
Department of Pediatrics, Renmin Hospital of Wuhan University.
Int Heart J. 2021;62(1):148-152. doi: 10.1536/ihj.20-180.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is erupting and spreading globally. Cardiovascular complications secondary to the infection have caught notice. This study aims to delineate the relationship of cardiac biomarkers and outcomes in severe cases of corona virus disease 2019 (COVID-19). One hundred forty-eight critically ill adult patients with COVID-19 were enrolled. From these patients, the demographic data, symptoms, cardiac biomarkers, treatments, and clinical outcomes were collected. Data were compared between survivors and non-survivors. Four patients in the non-survivor group were selected, and their cardiac biomarkers were collected and analyzed. Among the 148 patients, the incidence of cardiovascular complications was 19 (12.8%). Five of them were survivors (5.2%), and 14 of them were non-survivors (26.9%). Compared with the survivors, the non-survivors had higher levels of high-sensitivity cardiac troponin I, creatine kinase isoenzyme-MB, myoglobin, and N-terminal pro-brain natriuretic peptide (P < 0.05). The occurrence of cardiovascular events began at 11-15 days after the onset of the disease and reached a peak at 14-20 days. COVID-19 not only is a respiratory disease but also causes damage to the cardiovascular system. Cardiac biomarkers have the potential for early warning and prognostic evaluation in patients with COVID-19. It is recommended that cardiac biomarker monitoring in patients with COVID-19 should be initiated at least from the 11th day of the disease course.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）正在全球爆发和传播。感染引起的心血管并发症引起了关注。本研究旨在描绘心脏生物标志物与 2019 年冠状病毒病（COVID-19）重症病例结局的关系。纳入了 148 例患有 COVID-19 的重症成年患者。从这些患者中收集了人口统计学数据、症状、心脏生物标志物、治疗和临床结局。比较了幸存者和非幸存者的数据。从非幸存者组中选择了 4 例患者，收集并分析了他们的心脏生物标志物。在 148 例患者中，心血管并发症的发生率为 19（12.8%）。其中 5 例为幸存者（5.2%），14 例为非幸存者（26.9%）。与幸存者相比，非幸存者的高敏心肌肌钙蛋白 I、肌酸激酶同工酶-MB、肌红蛋白和 N 末端脑利钠肽前体水平更高（P<0.05）。心血管事件的发生始于发病后 11-15 天，在 14-20 天达到高峰。COVID-19 不仅是一种呼吸道疾病，还会对心血管系统造成损害。心脏生物标志物在 COVID-19 患者中有早期预警和预后评估的潜力。建议 COVID-19 患者的心脏生物标志物监测至少应在发病第 11 天开始。
